07.10.13
Tarrytown, NY
914.524.6800
www.prestigebrands.com
Sales: $175 million (estimated) for personal care and household products. Corporate sales: $623.6 million for the year ended March 31, 2013.
Key Personnel: Matthew M. Mannelly, president and CEO; Ron Lombardi, chief financial officer; Timothy J. Connors, executive vice president sales and marketing; Samuel C. Cowley, general counsel and VP, business development; John Parkinson, senior vice president, international; Jean Boyko, senior vice president, science and technology; Paul Hennessey, vice president, operations.
Major Products: Personal care, skin care, oral and OTC healthcare products including Chap-et Lip Balm, Cloverine, Debrox earwax remover, Dermoplast, Efferdent Denture Cleanser, Effergrip Denture Adhesive, Ezo denture, Gly-Oxide Oral Rinse, Kerodex, Kwellada-P Lice Treatment, Remedies, New-Skin Liquid Bandage, New-Skin Scar Fade, Outgro, Oxipor Psoriasis Lotion, The Doctor’s Night Guard. Household care products include Comet, Cinch and Spic and Span cleaners and Chore Boy scrubbing pads. The company also sells a number of GI-related medications and pain relievers for oral ingestion.
New Products: Efferdent Power Clean Crystals denture.
Comments: The company bills itself as the only independent, publicly-traded OTC company in the US. Corporate sales soared 41.5% primarily due to the growth of revenues of the company’s core OTC brands and a full year of ownership of acquired GSK brands. (In the prior year, the GSK brands contributed revenues for only the final two months of the fiscal year.)
For Prestige Brands, OTC is the future, as its home care business continues to shrink in importance.
For the fiscal year ended March 31, 2013, total revenues from home cleaning were just $86.6 million—just 13.9% of revenues, compared with 21.8% and 30.3% in 2012 and 2011, respectively.
“Our strategies are in place and we are fully prepared to build on the success of fiscal 2013. As the largest independent OTC products company in the US, we are confident in our ability to continue to build brands, innovate within our portfolio, and invest appropriately for future value creation,” said CEO Matthew M. Mannelly.
While OTC remedies may be the sexiest area for Prestige, some of the firm’s existing personal care and home brand hold impressive spots in their categories. For example, according to Prestige Brands, Efferdent Denture Cleanser (which Prestige considers a core brand) holds a 31.6% share and the No. 2 position in the $148 million denture cleanser tablets category, while Chore Boy holds an 11.7% share of the market and a No. 2 position in the Soap Free Metal Scrubbers market.
Meanwhile, New-Skin holds a 63.8% market share and the top position in the $23.4 million Liquid bandages market.
914.524.6800
www.prestigebrands.com
Sales: $175 million (estimated) for personal care and household products. Corporate sales: $623.6 million for the year ended March 31, 2013.
Key Personnel: Matthew M. Mannelly, president and CEO; Ron Lombardi, chief financial officer; Timothy J. Connors, executive vice president sales and marketing; Samuel C. Cowley, general counsel and VP, business development; John Parkinson, senior vice president, international; Jean Boyko, senior vice president, science and technology; Paul Hennessey, vice president, operations.
Major Products: Personal care, skin care, oral and OTC healthcare products including Chap-et Lip Balm, Cloverine, Debrox earwax remover, Dermoplast, Efferdent Denture Cleanser, Effergrip Denture Adhesive, Ezo denture, Gly-Oxide Oral Rinse, Kerodex, Kwellada-P Lice Treatment, Remedies, New-Skin Liquid Bandage, New-Skin Scar Fade, Outgro, Oxipor Psoriasis Lotion, The Doctor’s Night Guard. Household care products include Comet, Cinch and Spic and Span cleaners and Chore Boy scrubbing pads. The company also sells a number of GI-related medications and pain relievers for oral ingestion.
New Products: Efferdent Power Clean Crystals denture.
Comments: The company bills itself as the only independent, publicly-traded OTC company in the US. Corporate sales soared 41.5% primarily due to the growth of revenues of the company’s core OTC brands and a full year of ownership of acquired GSK brands. (In the prior year, the GSK brands contributed revenues for only the final two months of the fiscal year.)
For Prestige Brands, OTC is the future, as its home care business continues to shrink in importance.
For the fiscal year ended March 31, 2013, total revenues from home cleaning were just $86.6 million—just 13.9% of revenues, compared with 21.8% and 30.3% in 2012 and 2011, respectively.
“Our strategies are in place and we are fully prepared to build on the success of fiscal 2013. As the largest independent OTC products company in the US, we are confident in our ability to continue to build brands, innovate within our portfolio, and invest appropriately for future value creation,” said CEO Matthew M. Mannelly.
While OTC remedies may be the sexiest area for Prestige, some of the firm’s existing personal care and home brand hold impressive spots in their categories. For example, according to Prestige Brands, Efferdent Denture Cleanser (which Prestige considers a core brand) holds a 31.6% share and the No. 2 position in the $148 million denture cleanser tablets category, while Chore Boy holds an 11.7% share of the market and a No. 2 position in the Soap Free Metal Scrubbers market.
Meanwhile, New-Skin holds a 63.8% market share and the top position in the $23.4 million Liquid bandages market.